INTRODUCTION
The transthyretin (TTR)-related amyloidoses are rare, fatal protein misfolding and aggregation disorders. Historically, the TTR amyloidoses were grouped into three categories: (1) wild-type TTR amyloidosis (TTRwt), formerly known as senile systemic amyloidosis, presenting as a cardiomyopathy and involving the aggregation of wild-type (WT) TTR; (2) familial amyloid polyneuropathy (FAP); and (3) hereditary TTR amyloid cardiomyopathy, formerly known as familial amyloid cardiomyopathy (FAC). Both hereditary forms involve aggregation of primarily mutant TTR. Current knowledge suggests that the TTR amyloidoses do not fit neatly into these categories, as patients often exhibit a spectrum of phenotypes depending on mutation, genetic background, and extent of progression.
Non-fibrillar aggregates and amyloid composed of mutant and/or WT TTR of hepatic origin accumulate in various tissues and organs, particularly the peripheral and autonomic nerves and heart, leading to tissue damage and end-organ failure [1] [2] [3] . TTR gene expression by the choroid plexus and retinal pigmented epithelium leads to leptomeningeal and ocular degeneration linked to TTR amyloidogenesis, respectively [4] .
Tafamidis (2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid) is a once-daily, orally bioavailable, non-NSAID small molecule, and specific kinetic stabilizer of TTR [5] . In clinical studies, tafamidis slowed peripheral neurologic impairment and additional clinical manifestations in patients with Val30Met amyloidosis and was associated with an excellent safety profile [6] [7] [8] . Tafamidis is the first pharmacotherapy approved to treat TTR-FAP in the European Union and several countries in Latin America and the Asia-Pacific including Argentina and Japan.
The aim of this article is to focus on TTR as a drug target, to provide the rationale used in the development of tafamidis, and review comprehensively the pharmacology of this disease-modifying therapy for TTR amyloidoses. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
STRUCTURE AND FUNCTIONS OF TTR
Transthyretin, also known as prealbumin, is a soluble, b-sheet rich, 127-amino acid, non-glycosylated protein primarily synthesized and secreted into the blood by the liver. TTR circulates in the blood predominantly as a 55 kDa tetramer, along with a very small amount of dissociated monomer [6] . The monomeric subunits of TTR fold into a b-sandwich tertiary structure that spontaneously assembles into a tetramer within the cellular endoplasmic reticulum. The tetramer exhibits two distinct dimer-dimer interfaces, the less stable of which makes up two highly conserved thyroxine (T 4 ) binding sites [9] [10] [11] [12] [13] . The three-dimensional structures of the TTR tetramer bound to T 4 and its other known ligand, the vitamin A-retinol-binding protein complex, have been solved [14] [15] [16] .
Transthyretin is expressed from embryonic development through adult life and its blood concentration over this time reflects those of total body nitrogen and total body potassium levels [17] . Serum TTR concentration so closely mimics the body's nitrogen balance that it has been widely used as a marker of malnutrition and inflammation in several conditions [17] [18] [19] . In fact, TTR is a negative acute phase reactant [20] .
In In blood, the TTR tetramer binds retinol-binding protein bound to retinol (holo-retinol-binding protein) and a small amount of T 4 , and transports them to tissues on the minute-to-hour timescale [9, 26, 27] .
Although TTR is the only known transporter of circulating holo-retinol-binding protein that facilitates retinol transport, two other proteins, namely, albumin and thyroid binding globulin transport thyroid hormones. Of the three T 4 binding proteins, albumin has by far the highest plasma concentration and thyroid binding globulin has the highest affinity for T 4 [28, 29] . Thus, given the low level of circulating T 4 , less than 10% of T 4 in blood is bound to TTR and more than 99% of the T 4 binding sites in circulating TTR are vacant [21] . Thus, TTR is thought to play only a minor role in the physiological transport of T 4 . In contrast, TTR is the primary T 4 carrier in cerebrospinal fluid [10] .
In addition, transthyretin may be a natural detoxifier, as its T 4 binding sites bind small molecules with substituted aromatic rings connected by linkers of variable chemical composition [30] . These structures include stilbenes, flavones, benzoxazoles, tetrahydroquinolines, dihydropyridines, benzodiazepines, and phenoxazines [31, 32] .
Emerging evidence suggests that WT TTR may also have a protective effect in Alzheimer's disease through an interaction with the amyloidogenic Ab-amyloid peptide [30] . TTR has also been shown to influence nerve physiology and to enhance nerve regeneration in the mouse [33] . A role for TTR in nerve biology and repair may explain the preferential deposition of mutant TTR aggregates in the peripheral nervous system of patients with TTR-FAP [33] .
MOLECULAR MECHANISM OF TTR AMYLOIDOGENESIS
Experiments with cell lines and Drosophila melanogaster model systems demonstrate the proteotoxicity associated with various TTR sequences linked to pathology [3, [34] [35] [36] [37] [38] [39] .
Biophysical in vitro studies suggest that tetrameric TTR protein does not form amyloid fibrils and that amyloidogenesis starts with TTR tetramer dissociation into dimers, which then rapidly dissociate to folded monomers (Fig. 1a) [23, [40] [41] [42] [43] [44] [45] . Amyloid fibrillogenesis appears to require partial denaturation of released monomers, which exposes stretches of hydrophobic residues that misassemble into spherical aggregates which then undergo conformational conversion into cross-b sheet assemblies [46] [47] [48] [49] [70] [71] [72] . TTR-FAP is characterized by a length-dependent sensory, motor, and autonomic neuropathy [68] . Gastrointestinal symptoms are a common complication of autonomic neuropathy.
Amyloid deposits, typically found in ganglia, the endoneurium, and nerve blood vessels, lead to the reduction of nerve fiber density and eventual destruction of unmyelinated nerve fibers, and then small and large myelinated nerve fibers [68, 73] . Distal axonal degeneration is the main pathogenic feature. Possible underlying mechanisms that are not mutually exclusive include: (1) a combination of toxic and mechanical effects of fibrillar amyloid deposits on nerve fibers [68, 74] ; and/or (2) the proteotoxicity of non-amyloid TTR aggregates [2, 3] . Clinical manifestations of cardiac involvement may follow later in the course of disease; however, echocardiography in patients with only neurologic symptoms may reveal features of cardiac amyloidosis and electrocardiography can reveal conduction defects early in the course of the condition [75, 76] . In some TTR mutants such as Thr60Ala (p.Thr80Ala), cardiac involvement may be seen early or as the first phenotypic manifestation [77] , early and frequent carpal tunnel syndrome, predominant negative sensory symptoms at onset, significant vibration deficits, as well as a non-length-dependent progression of motor deficit are also characteristic [78] ; while for patients with the Ser77Tyr mutation, the distinguishable features are late-onset ([50 years) of disease and frequent ataxic phenotype [79] . Neurologic and cardiac deterioration progress relentlessly during active TTR amyloidogenesis, typically leading to death within 5-15 years of symptom onset [66] . It is worth noting that for patients with the Val30Met mutation and whose disease onset occurs at an older age ([50 years), studies of the disease history revealed that the initial manifestation of amyloidosis was somatic neuropathy, and the mean duration of the disease onset to death was 7.3 years [76] .
However, for many late-onset cases, due to the inconspicuous nature of the symptoms (i.e., autonomic dysfunctions and sensory dissociation), they are often misdiagnosed as other neuropathies [75] . In addition, distinctive clinical presentation has been found in late-onset cases with the Val30Met mutation from non-endemic areas that differs from that of conventional early-onset cases in endemic foci [79, 80] . Consequently, late-onset cases are still under-recognized and an appropriate diagnosis may benefit from examinations for subclinical cardiac amyloidosis.
In the exclusive or predominant cardiac phenotype, known as hereditary TTR amyloid cardiomyopathy, amyloid is found throughout the cardiovascular system, including the valves, ventricles, atria, and the conduction system, leading to left ventricular wall thickening with a non-dilated left ventricle and impaired longitudinal contraction, and resulting in congestive heart failure and arrhythmias [67, 73, 81] . Survival data for hereditary TTR amyloid cardiomyopathy are not as well documented as for TTR-FAP, but the prognosis is known to be poor with median survival from Neurol Ther (2016) 5:1-25diagnosis ranging from 25.6 to 36.4 months in three small series [82] [83] [84] , and with death primarily from heart failure or sudden death [85] . The most common mutation associated with TTR amyloid cardiomyopathy is Val122Ile (p.Val142Ile), which is found in up to 4% of African Americans [86, 87] . The level of penetrance of this mutation has yet to be fully elucidated [87] ; 10% of Afro-Caribbean patients with acute decompensated heart failure carry the Val122Ile mutation [88] . Other pathogenic TTR mutations are less prevalent, and often lead to a more 'mixed' phenotype of neurologic and multi-organ system involvement [67] .
In TTRwt amyloidosis, WT TTR tetramers dissociate into monomers, misfold, and undergo amyloidogenesis. Biopsies from gastrointestinal tract and subcutaneous tissue of TTRwt amyloidosis patients confirmed amyloid deposits in 44% (4/9) of the samples [89] . At autopsy, up to 22-25% of individuals [80 years of age, and 32% of adults over the age of 75 with heart failure and a preserved ejection fraction, have demonstrable TTR amyloid deposits in cardiac tissue (mainly found inside the ventricular wall in a patchy plaque-like shape) albeit usually mild in extent [85, 89, 90] . The process is not well understood but seems to be related to ageing and possibly to destabilizing post-translational modifications.
Cardiac amyloidosis is the primary feature of those exhibiting active TTRwt amyloidosis, generally a late-onset sporadic condition 
AUC mean area under the concentration-time curve, CI confidence interval, C max maximum plasma concentration, C min minimum plasma concentration, PK pharmacokinetic, SD standard deviation, SS steady state, T max time to reach C max , Vc/F volume of distribution of the central compartment, Vp/F volume of distribution of the peripheral compartment primarily affecting men [62] . In two separate observational studies, the prevalence of sensory neuropathy among patients with symptomatic TTRwt amyloidosis was around 28% and nearly half had a history of carpal tunnel syndrome apparently owing to amyloid deposition in the connective tissue of the transverse carpal ligament [69, 84] . CI confidence interval, EE population efficacy-evaluable population defined as all randomized patients who received C1 dose of study drug, had C1 post-baseline assessment for both co-primary endpoints, and completed the study per protocol (tafamidis, n = 45; placebo, n = 42), ITT population intent-to-treat population, LS mean least square mean, NIS-LL neuropathy impairment score-lower limb, NIS-UL neuropathy impairment score-upper limb, percentile range 25th to 75th percentile, NYHA New York Heart Association, SD standard deviation, SEM standard error of the mean, TQOL self-reported quality of life score (from the Norfolk Quality of Life-Diabetic Neuropathy questionnaire), TRACS Transthyretin Amyloidosis Cardiac Study, TTR transthyretin a Percentage stabilization values (post-treatment relative to pre-treatment) falling above the upper 95% CI of mean percent stabilization in placebo-treated healthy volunteers were considered to be ' 'stabilized' ' [99] , attention turned to the benzoxazole carboxylic acids. Of these, tafamidis (Fig. 1b, c) was selected for clinical development due to its lack of NSAID-activity, good oral bioavailability, and low toxicity profile.
RATIONALE FOR DEVELOPMENT OF TAFAMIDIS

CLINICAL PHARMACOKINETICS OF TAFAMIDIS
Tafamidis is highly bound to plasma proteins and C min(ss) at 2.7 and 1.6 lg/mL, respectively (Table 1) [100, 101] .
Based on population PK analysis, SS clearance of tafamidis was similar in subjects with creatinine clearance \80 and [80 mL/min. However, compared with healthy volunteers, patients with moderate hepatic impairment (Child-Pugh Score of 7-9 inclusive) had decreased systemic exposure (by approximately 40%) of tafamidis. In subjects [60 years old, clearance following repeated tafamidis 20 mg once daily was 19% slower and the C max(ss) was 21% higher compared with those \60 years old [100] .
TTR STABILIZATION BY TAFAMIDIS
Nonclinical in vitro and ex vivo experiments have demonstrated that tafamidis binds with selectivity, high affinity, and negative cooperativity (K D1 * 2 nM, K D2 * 200 nM) to recombinant WT TTR and to TTR in human plasma [5, 102] . Tafamidis exhibits comparable potency against dissociation of WT TTR and heterotetramers of [35 TTR mutants, including the two most common amyloidogenic mutants, Val30Met and Val122Ile [5] .
As stated in previous publications [5, 102] , an indirect means of detecting TTR monomer formation under physiologic conditions is to employ subunit exchange experiments [42, 103, 104] , in which, two homotetramers composed of WT TTR subunits with and without the N-terminal negatively charged FLAG-tag were mixed, and time-dependent subunit exchange was then quantified using ion-exchange chromatography at physiologic pH. Since TTR tetramer dissociation should be slowed by tafamidis, the subunit exchange between the untagged WT TTR homotetramer and the FLAG-tagged WT TTR homotetramer would be slowed in the presence of tafamidis.
Experiments showed that subunit exchange was complete in the vehicle control after 96 h of incubation at 25°C when the pH was 7.0; while in the presence of tafamidis, the fraction of subunit exchange was considerably lower.
For instance, at a tafamidis:TTR tetramer molar ratio of 1, the subunit exchange was 15% after 24 h compared with 70% in the absence of tafamidis; and when the molar ratio was 1.50, the fraction of exchange was\10% after 11 days [5] . Based on these findings, it has been concluded that tafamidis decreases the rate of tetramer dissociation at physiologic pH in a dose-dependent manner.
By measuring TTR tetramers in plasma, an immunoturbidimetric assay [98] (for details see the supplementary material) was used in nonclinical and clinical studies to measure a key pharmacodynamic endpoint as it demonstrated that tafamidis stabilized TTR mutants ex vivo [5] . In this assay, 4.8 lM urea was added to plasma samples for over 48 h, which was followed by glutaraldehyde crosslinking, and then the remaining tetrameric TTR was quantified using a TTR antibody [5, 98, 102] [40] [41] [42] [43] [44] [45] . Also shown are the molecular structure of tafamidis (b) and the co-crystal structure of tafamidis (black, ball-and-stick) bound to a TTR tetramer (ribbon) (c). TTR transthyretin a 1-1.5:1 tafamidis:TTR stoichiometry should be sufficient to stabilize TTR and inhibit tetramer dissociation in human plasma (Pfizer, data on file). In two clinical studies of healthy volunteers with orally administered tafamidis, mean percent TTR stabilization increased with increasing plasma tafamidis:TTR stoichiometry and appeared to reach a plateau (Fig. 2 ), but at ratios higher than projected from nonclinical data. Evidence showed that tafamidis binds and stabilizes the functional TTR protein (i.e., the tetrameric form) and the stabilized tetramers are less likely to dissociate into monomers; however, the relationship between increased TTR stabilization and the increase in concentration of circulating functional TTR requires further investigation [7, 8, 102] . (placebo-tafamidis) for 12 months, tafamidis conferred increased TTR tetramer stability in [93% of participants. Moreover, the observed slowing of disease progression among the tafamidis-treated patients of Fx-005 was extended to 30 months in the tafamidis-tafamidis cohort and the rate of disease progression was reduced in the placebo-tafamidis group over the 12-month active treatment period (Fig. 4) [8]. [7, 8, 106] . ITT intention to treat Patients in these trials had variable characteristics and severity of symptoms at baseline. Therefore, the differences observed in clinical efficacy and safety across these trials may be confounded by the patients' underlying disease and comorbid conditions.
TTR TETRAMER STABILIZATION IN PLASMA OF TTR AMYLOIDOSIS PATIENTS
THERAPEUTIC USE
SAFETY
Adverse Events
The risk of adverse events (AEs) is difficult to evaluate based on the small number of patients who received tafamidis to date. The available clinical trial data indicate that tafamidis was generally well tolerated, with the type and frequency of the most commonly reported AEs partly dependent on the primary phenotype and clinical status of the patient in addition to any drug effects. Many of the AEs with an overall incidence [5% are of a similar nature as the symptoms of the underlying disease.
In the Fx-005 study of patients with early-stage Val30Met-FAP, the overall incidences of any AE, AE leading to drug discontinuation, and serious AEs were similar in the tafamidis and placebo treatment groups [7] . Furthermore, the overall incidence rates of AEs among the polyneuropathy patients in studies Fx-005, Fx-006, and Fx1A-201 were similar [7, 8, 106] . Differences in incidence rates of individual AEs across these studies were generally not clinically meaningful. One exception was treatment-emergent urinary tract infection (UTI): 15 of 65 tafamidis-treated patients (23%) in Fx-005 reported a UTI compared with 8 of 63 placebo-treated patients (13%) [7] . UTIs were also reported by 12 of 85 tafamidis-treated patients (14%) in In the Fx1B-201 study of TTR amyloid cardiomyopathy, 15 of 35 patients had a serious AE, the most common being cardiac disorders (12 patients) including heart failure (9 patients) and atrial fibrillation (3 patients) [107] . Four patients reported six SAEs that were considered possibly related to tafamidis, namely, syncope, ataxia, falls (reported by two patients), hemorrhagic stroke, and cardiac heart failure [107] .
Deaths
In the Fx-005 study, five Val30Met-FAP patients (two receiving tafamidis, three receiving placebo) died, all after liver transplant [7] .
These deaths were considered unrelated to the study drug. No deaths were reported in Fx-006 or Fx1A-201 [8, 106] .
Two TTRwt amyloidosis patients died during the Fx1B-201 study (causes of death were hemorrhagic stroke and amyloid light-chain
[AL] amyloidosis) [107] . These deaths were considered unrelated to the study drug. The patient with AL amyloidosis had been enrolled in the study based on positive amyloid biopsy, absence of evidence of a plasma cell dyscrasia, and positive TTR staining by immunogold electron microscopy. After an unexplained, rapid decline at 11 months, a re-biopsy demonstrated amyloid positive for immunoglobulin light chain and no evidence of TTR deposition, after which the patient withdrew from the study, and died from complications due to pleurodesis treatment for AL amyloidosis. Subsequent re-evaluation of the biopsies using mass spectrometry demonstrated that both had amyloid deposits derived from light chains, without evidence of TTR.
DISCUSSION
The nonclinical and clinical studies described here demonstrate that tafamidis kinetically stabilizes TTR tetramers thereby slowing TTR tetramer dissociation. TTR tetramer disassembly is the rate-limiting step of amyloidogenesis and its inhibition is expected to inhibit the amyloidogenesis cascade and, in turn, to slow disease progression. Strong evidence for this concept was that tafamidis treatment slowed neurologic disease progression in patients with
Val30Met amyloidosis compared with placebo [7] , and by the fact that modest deterioration in neurologic function was observed in patients with TTR-FAP caused by non-Val30Met mutations and who were treated with tafamidis [106] . amyloidosis who were treated with tafamidis, the rate of neurologic deterioration was slowed, quality of life was maintained, and nutritional status was improved, compared with placebo-treated patients [7, 108] ; and TTR stabilization was associated with slower disease progression [8] . There was also some indication that 12 months of open-label tafamidis might improve some signs and symptoms of TTR-FAP associated with non-Val30Met mutations in older patients with more advanced disease [106] . Considering the mechanism of action and the available results on TTR stabilization, the tafamidis effect on disease progression is expected to extend to TTR amyloid polyneuropathy due to non-Val30Met mutations [106] .
Long-term study demonstrated that the clinical benefits experienced by Val30Met-FAP patients receiving tafamidis were sustained for the duration of the study (30 
